S&P Futures
5,968.25 +10.00 (+0.17%) Dow Futures
44,008.00 +107.00 (+0.24%) Nasdaq Futures
20,932.50 +38.50 (+0.18%) Russell 2000 Futures
2,412.20 +6.40 (+0.27%) Crude Oil
72.03 +0.34 (+0.47%) Gold
2,665.00 -11.30 (-0.42%)
Ventyx Biosciences, Inc. (VTYX)
After hours:
| Previous Close | 2.1800 |
| Open | 2.2700 |
| Bid | 2.3000 x 100 |
| Ask | 2.3600 x 100 |
| Day's Range | 2.2000 - 2.3550 |
| 52 Week Range | 1.7900 - 11.4800 |
| Volume | |
| Avg. Volume | 1,166,047 |
| Market Cap | 164.659M |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9600 |
| Earnings Date | Nov 06, 2024 - Nov 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
TipRanksThese 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
In his iconic song The Gambler, Kenny Rogers famously sang, “Every hand’s a winner, and every hand’s a loser.” This line offers valuable wisdom for investors: no matter the strategy, success in the stock market ultimately depends on how well you navigate the balance between risk and reward. Few corners of the stock market present a greater potential return for the risk than penny stocks, which trade at $5 or less. These ultra-low-priced equities offer an attractive entry point for investors look
GlobeNewswireVentyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Late-breaking abstract highlights high rates of clinical and endoscopic remission among LTE completers at Week 52SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of
